Yahoo Malaysia Web Search

Sign In

Search results

  1. www.biomarin.comBioMarin Pharmaceutical Inc.

    Jun 28, 2024 · BioMarin develops and markets medicines for life-threatening genetic conditions, such as achondroplasia, hemophilia A, and PKU. Learn about their breakthrough science, patient focus, and people-first culture.

    • Our Science

      At BioMarin, we’re committed to delivering on the promise of...

    • Our Treatments

      Products and Pipeline. For more than two decades, we have...

    • Our Company

      BioMarin is a global biotechnology company that relentlessly...

    • Investors & Media

      At Biomarin Pharmaceutical Inc., we promise to treat your...

  2. en.wikipedia.org › wiki › BioMarin_PharmaceuticalBioMarin Pharmaceutical - Wikipedia

    BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs).

  3. Videos

    View all

  4. www.biomarin.com › companyAbout Us | BioMarin

    BioMarin develops and commercializes medicines for rare and inherited conditions, using enzyme replacement, gene therapy and other modalities. Founded in 1997, BioMarin has eight approved products and a diverse pipeline of candidates.

  5. finance.yahoo.com › quote › BMRNBioMarin Pharmaceutical Inc. (BMRN) - Yahoo Finance

    BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an...

  6. www.biomarin.com › products-and-pipelineProducts and Pipeline | BioMarin

    BioMarin is a biopharmaceutical company that develops and commercializes therapies for rare diseases based on genetic insights. Learn about its eight approved products and its robust pipeline of clinical-stage and preclinical programs.

  7. investors.biomarin.com › news › news-detailsBioMarin Pharmaceutical Inc. - BioMarin Announces Strong Third...

    Nov 1, 2023 · In the third quarter, patient growth remained strong worldwide. Based on these trends, and the expectation that approximately 2,600 children will be receiving VOXZOGO treatment by year-end, today the company updated full-year 2023 VOXZOGO guidance to between $435 million and $455 million.

  8. investors.biomarin.com › news › news-detailsBioMarin Pharmaceutical Inc. - First Gene Therapy for Adults with...

    Aug 24, 2022 · Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity. Significant Benefit Over Existing Therapies for Patients with Severe Hemophilia A in EU Based on EMA Determination of ODD. Conference Call and Webcast to be Held Wed., Aug. 24th at 8:00 pm Eastern.